Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence

Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases

(2011) Carlos G. Grijalva et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adverse Cutaneous Reactions Induced by TNF-α Antagonist Therapy

(2011) Joaquín Borrás-Blasco et al.   SOUTHERN MEDICAL JOURNAL

Definition of treatment goals for moderate to severe psoriasis: a European consensus

(2010) U. Mrowietz et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

(2010) Wolfgang Weger   BRITISH JOURNAL OF PHARMACOLOGY

Improving clinical trial design in psoriasis: Perspectives from the global dermatology community

(2010) Peter van de Kerkhof et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Intermittent etanercept therapy in pediatric patients with psoriasis

(2010) Elaine C. Siegfried et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term etanercept in pediatric patients with plaque psoriasis

(2010) Amy S. Paller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence

(2010) PA Foley et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

(2010) V Bronsard et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

(2010) E Puzenat et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The Future of Biological Therapies

(2010) Richard B. Warren et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

(2009) X Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

(2009) J.-P. Ortonne et al.   BRITISH JOURNAL OF DERMATOLOGY

Phototherapy for psoriasis: what to choose and how to use: facts and controversies

(2009) Hagit Matz   CLINICS IN DERMATOLOGY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

(2009) D Pathirana et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Economic Burden of Psoriatic Arthritis

(2009) Christoph Ackermann et al.   PHARMACOECONOMICS

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

(2008) J Askling et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term prognosis in patients with psoriasis

(2008) W. Gulliver   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis comorbidities

(2008) Alice B. Gottlieb et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

(2008) Amy S. Paller et al.   NEW ENGLAND JOURNAL OF MEDICINE